Severity of Coronavirus Disease 19: A Profile of Inflammatory Markers in Iraqi Patients

Main Article Content

Ali H. Ad’hiah
Rasha M. A. Al-Humairi
Hanan Y. Muhsin

Abstract

Introduction: Accumulating evidence indicates that inflammatory responses play a major role in the development and/or severity of coronavirus disease 2019 (COVID-19). Therefore, a retrospective, cross-sectional study was performed to provide an inflammatory profile in COVID-19. Methods: The study included 139 patients infected with COVID-19, who were admitted to inpatient wards and intensive care units in Baghdad Teaching Hospital. There were 105 patients suffering from non-severe illness and 34 patients had severe disease. This study simultaneously evaluated six peripheral blood markers of inflammation to determine their predictive value in COVID-19 severity. These were C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, D-dimer, lactate dehydrogenase (LDH) and neutrophil-to-lymphocyte ratio (NLR). Results: The medians of age, CRP, ESR, ferritin, D-dimer and NLR were significantly elevated in severe cases of COVID-19 compared to non-severe cases. The LDH also tended to have increased levels in severe cases but the difference was not significant compared to non-severe cases. Logistic regression analysis demonstrated that D-dimer was the most significant risk factor, followed by NLR, ferritin and CRP. Receiver operating characteristic (ROC) curve analysis identified that the best cut-off values of CRP, ESR, ferritin, D-dimer, LDH and NLR for predicting severity in COVID-19 patients were 22.7 mg/L, 59.5 mm/h, 719.4 ng/mL, 367.5 ng/mL, 468.5 U/L and 12.9, respectively. Conclusion: Age and the inflammatory markers CRP, ESR, ferritin, D-dimer, and NLR showed higher medians in severe cases of COVID-19 compared to non-severe cases. In this context, D-dimer and NLR are suggested to be important predictive markers of severe disease.

Downloads

Download data is not yet available.

Article Details

How to Cite
Ad’hiah, A. H., Al-Humairi, R. M. A., & Muhsin, H. Y. (2024). Severity of Coronavirus Disease 19: A Profile of Inflammatory Markers in Iraqi Patients. Malaysian Journal of Medicine and Health Sciences, 18(1), 91–98. Retrieved from http://mjmhsojs.upm.edu.my/index.php/mjmhs/article/view/297
Section
Original Articles

References

World Health Organization (WHO). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [Internet]. Geneva, Switzerland. 2020 [cited 2021 Mar 12]. p. 1–6. Available from: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)

Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents [Internet]. 2020 May 1 [cited 2020 Aug 22];55(5):105951. Available from: /pmc/articles/PMC7139247/?report=abstract

WHO. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. Who.int. 2021 [cited 2021 Mar 12]. Available from: https://covid19.who.int/

Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol [Internet]. 2020 Aug 25 [cited 2020 Sep 8];jmv.26424. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26424

Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep [Internet]. 2021 Dec 19 [cited 2021 Mar 11];11(1):4263. Available from: http://www.nature.com/articles/s41598-021-82862-5

García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 [Internet]. Vol. 11, Frontiers in Immunology. Frontiers Media S.A.; 2020 [cited 2021 Mar 13]. p. 1441. Available from: /pmc/articles/PMC7308593/

Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell [Internet]. 2020 May 28 [cited 2021 Mar 13];181(5):1036-1045.e9. Available from: https://pubmed.ncbi.nlm.nih.gov/32416070/

Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis [Internet]. Vol. 25, European Journal of Medical Research. BioMed Central; 2020 [cited 2021 Mar 13]. p. 30. Available from: https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-020-00432-3

Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19. Medicine (Baltimore) [Internet]. 2020 Nov 20 [cited 2021 Mar 12];99(47):e23315. Available from: https://journals.lww.com/10.1097/MD.0000000000023315

World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance 28 January 2020 [Internet]. Who. 2020. p. 10. Available from: WHO/2019-nCoV/clinical/2020.5%0ACC BY-NC-SA 3.0 IGO%0AWHO/2019-nCoV/clinical/2020.5%0ACC BY-NC-SA 3.0 IGO%0Ahttps://apps.who.int/iris/handle/10665/330893e

Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. Solomon CG, editor. N Engl J Med [Internet]. 2020 Oct 29 [cited 2021 Mar 16];383(18):1757–66. Available from: http://www.nejm.org/doi/10.1056/NEJMcp2009249

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ [Internet]. 2020 Mar 26 [cited 2021 Mar 14];368. Available from: https://pubmed.ncbi.nlm.nih.gov/32217556/

Chen TL, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical Characteristics and Outcomes of Older Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective Study. Journals Gerontol - Ser A Biol Sci Med Sci [Internet]. 2020 Jun 5 [cited 2021 Mar 14];75(9):1788–95. Available from: https://pubmed.ncbi.nlm.nih.gov/32279081/

Farghaly S, Makboul M. Correlation between age, sex, and severity of Coronavirus disease-19 based on chest computed tomography severity scoring system. Egypt J Radiol Nucl Med [Internet]. 2021 Dec 1 [cited 2021 Mar 14];52(1):23. Available from: https://ejrnm.springeropen.com/articles/10.1186/s43055-021-00408-1

Starke KR, Petereit-Haack G, Schubert M, Kämpf D, Schliebner A, Hegewald J, et al. The age-related risk of severe outcomes due to covid-19 infection: A rapid review, meta-analysis, and meta-regression. Int J Environ Res Public Health [Internet]. 2020 Aug 2 [cited 2021 Mar 14];17(16):1–24. Available from: /pmc/articles/PMC7460443/

Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. J Intensive Care [Internet]. 2020 Jul 10 [cited 2021 Mar 18];8(1):49. Available from: https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-020-00466-z

Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay A, Seyit M, et al. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med [Internet]. 2021 Feb 1 [cited 2021 Mar 18];40:55–9. Available from: https://pubmed.ncbi.nlm.nih.gov/33348224/

Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly [Internet]. Vol. 39, International Journal of Laboratory Hematology. Blackwell Publishing Ltd; 2017 [cited 2021 Mar 18]. p. 98–103. Available from: https://pubmed.ncbi.nlm.nih.gov/28447414/

Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ILL patients. Chest [Internet]. 2002 Apr 1 [cited 2021 Mar 18];121(4):1262–8. Available from: http://journal.chestnet.org/article/S0012369215343099/fulltext

Notz Q, Schmalzing M, Wedekink F, Schlesinger T, Gernert M, Herrmann J, et al. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. Front Immunol [Internet]. 2020 Oct 6 [cited 2021 Mar 18];11:581338. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2020.581338/full

Kaur S, Bansal R, Kollimuttathuillam S, Gowda AM, Singh B, Mehta D, et al. The looming storm: Blood and cytokines in COVID-19 [Internet]. Vol. 46, Blood Reviews. Churchill Livingstone; 2020 [cited 2021 Mar 18]. p. 100743. Available from: /pmc/articles/PMC7431319/

Chaplin DD. Overview of the immune response. J Allergy Clin Immunol [Internet]. 2010 Feb [cited 2021 Mar 18];125(2 SUPPL. 2):S3. Available from: /pmc/articles/PMC2923430/

Aktas G, Sit M, Dikbas O, Erkol H, Altinordu R, Erkus E, et al. Elevated neutrophil-to-lymphocyte ratio in the diagnosis of Hashimoto’s thyroiditis. Rev Assoc Med Bras [Internet]. 2017 Dec 1 [cited 2021 Mar 18];63(12):1065–8. Available from: http://dx.doi.org/10.1590/1806-9282.63.12.1065

Song H, Kim HJ, Park KN, Kim SH, Oh SH, Youn CS. Neutrophil to lymphocyte ratio is associated with in-hospital mortality in older adults admitted to the emergency department. Am J Emerg Med [Internet]. 2021 Feb 1 [cited 2021 Mar 19];40:133–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32008828/

Yang AP, Liu J ping, Tao W qiang, Li H ming. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol [Internet]. 2020 Jul 1 [cited 2021 Mar 19];84:106504. Available from: /pmc/articles/PMC7152924/

Li X, Liu C, Mao Z, Xiao M, Wang L, Qi S, et al. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care [Internet]. 2020 Dec 1 [cited 2021 Mar 19];24(1):647. Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03374-8

Jimeno S, Ventura PS, Castellano JM, García-Adasme SI, Miranda M, Touza P, et al. Prognostic implications of neutrophil-lymphocyte ratio in COVID-19. Eur J Clin Invest [Internet]. 2021 Jan 1 [cited 2021 Mar 19];51(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32918295/

Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection [Internet]. Vol. 9, Frontiers in Immunology. Frontiers Media S.A.; 2018 [cited 2021 Mar 19]. p. 754. Available from: /pmc/articles/PMC5908901/

Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J [Internet]. 2021 Jan 15 [cited 2021 Mar 19]; Available from: https://pubmed.ncbi.nlm.nih.gov/33448289/

Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020 Jun 1;50(4):332–4.

Lapić I, Rogić D, Plebani M, Plebani M. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): A pooled analysis [Internet]. Vol. 58, Clinical Chemistry and Laboratory Medicine. De Gruyter; 2020 [cited 2021 Mar 19]. p. 1146–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32386190/

Kappert K, Jahić A, Tauber R. Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. Biomarkers [Internet]. 2020 Nov 16 [cited 2021 Mar 19];25(8):616–25. Available from: https://www.tandfonline.com/doi/full/10.1080/1354750X.2020.1797880

Gómez-Pastora J, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, et al. Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator? [Internet]. Vol. 509, Clinica Chimica Acta. Elsevier B.V.; 2020 [cited 2021 Mar 19]. p. 249–51. Available from: /pmc/articles/PMC7306200/

Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med [Internet]. 2020 Sep 1 [cited 2021 Mar 19];38(9):1722–6. Available from: /pmc/articles/PMC7251362/